These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2978385)

  • 41. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.
    Sader HS; Jones RN
    Int J Antimicrob Agents; 2005 May; 25(5):380-4. PubMed ID: 15848291
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carumonam versus ceftazidime: in vitro activity, pharmacokinetics in elderly patients, safety and therapeutic efficacy in the treatment of complicated urinary tract infections.
    Naber K; Kees F; Denk K; Bauernfeind A; Grobecker H
    Chemioterapia; 1987 Jun; 6(2 Suppl):517-8. PubMed ID: 3334613
    [No Abstract]   [Full Text] [Related]  

  • 43. Antibacterial activity of coumermycin alone and in combination with other antibiotics.
    Neu HC; Chin NX; Labthavikul P
    Antimicrob Agents Chemother; 1984 Jun; 25(6):687-9. PubMed ID: 6331295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa.
    Righter J
    Eur J Clin Microbiol; 1984 Aug; 3(4):368-9. PubMed ID: 6436021
    [No Abstract]   [Full Text] [Related]  

  • 45. [On flucloxacillin sensitivity determination by the disc method (author's transl)].
    Kanazawa Y; Kuramata T
    Jpn J Antibiot; 1975 Feb; 28(1):48-52. PubMed ID: 1092891
    [No Abstract]   [Full Text] [Related]  

  • 46. Antibacterial activity and synergy, in vitro and in vivo, of a combination of amoxycillin and flucloxacillin.
    Comber KR; Merrikin DJ; Sutherland R
    Chemotherapy; 1979; 25(1):30-9. PubMed ID: 253636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro studies on SQ 26,776, a new monobactam antibiotic.
    Russell AD
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():81-8. PubMed ID: 6799485
    [No Abstract]   [Full Text] [Related]  

  • 48. The potential impact on clinical practice of differences in the in-vitro activity of vancomycin and teicoplanin.
    Cheesbrough JS; Smith SR; Davies JM
    J Antimicrob Chemother; 1990 Apr; 25(4):716-8. PubMed ID: 2141019
    [No Abstract]   [Full Text] [Related]  

  • 49. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.
    Calain P; Krause KH; Vaudaux P; Auckenthaler R; Lew D; Waldvogel F; Hirschel B
    J Infect Dis; 1987 Feb; 155(2):187-91. PubMed ID: 2949024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bacteriological studies on synergism between amoxicillin and flucloxacillin (author's transl)].
    Ochiai H; Terao M; Miyamura S
    Jpn J Antibiot; 1976 Dec; 29(12):1042-7. PubMed ID: 1051433
    [No Abstract]   [Full Text] [Related]  

  • 51. Structure and mechanism of action of teicoplanin.
    Parenti F
    J Hosp Infect; 1986 Mar; 7 Suppl A():79-83. PubMed ID: 2871101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synchrotron radiation infrared microspectroscopy to assess the activity of vancomycin against endocarditis vegetation bacteria.
    Batard E; Jamme F; Montassier E; Bertrand D; Caillon J; Potel G; Dumas P
    J Microbiol Methods; 2011 Jun; 85(3):235-8. PubMed ID: 21447359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Carumonam: antibacterial activity in vitro].
    Garlaschi ML; Lombardi A; Castiglioni G; Abbiati R; Varotto F
    G Ital Chemioter; 1991; 38(1-3):185-7. PubMed ID: 1365586
    [No Abstract]   [Full Text] [Related]  

  • 54. [In vitro and in vivo antibacterial activity of combined flucloxacillin-cefacetrile (Flunicef)].
    Venturini AP; Stanzani L; Mantovani V; Mascellani G
    G Ital Chemioter; 1979; 26(1-2):153-8. PubMed ID: 554805
    [No Abstract]   [Full Text] [Related]  

  • 55. Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients.
    Smith CL; Milliken S; Powles R; Da Costa F; Gore M; Benjamin S; Talbot D; Ellis L; Large J; Jameson B
    Br J Haematol; 1990 Dec; 76 Suppl 2():6-9. PubMed ID: 2149055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Rm values of newer penicillins for investigating their spectrum of antibacterial activity.
    Biagi GL; Guerra MC; Barbaro AM; Cantelli-Forti G; Rossi T
    Boll Soc Ital Biol Sper; 1975 Apr; 51(7):403-5. PubMed ID: 1044282
    [No Abstract]   [Full Text] [Related]  

  • 57. [Blood levels of amoxicillin in humans after oral administration, singly or in combinations].
    Benoni G; Minelli Bertazzoni E; Berti T
    Clin Ter; 1978 Aug; 86(4):311-8. PubMed ID: 367680
    [No Abstract]   [Full Text] [Related]  

  • 58. Summation: beta-lactam resistance surveillance in the Asia-Western Pacific region.
    Jones RN
    Diagn Microbiol Infect Dis; 1999 Dec; 35(4):333-8. PubMed ID: 10668593
    [No Abstract]   [Full Text] [Related]  

  • 59. Influence of various antibiotics on phagocytosis of Staphylococcus aureus by human polymorphonuclear leucocytes.
    Van der Auwera P; Husson M; Frühling J
    J Antimicrob Chemother; 1987 Sep; 20(3):399-404. PubMed ID: 3680077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergy study of carumonam and ceftazidime with aminoglycosides.
    Ahmet Z; Houang E
    J Antimicrob Chemother; 1987 Aug; 20(2):288-90. PubMed ID: 3312142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.